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ARTICLE
The mechanism of a high-affinity allosteric inhibitor
of the serotonin transporter
Per Plenge1,7, Ara M. Abramyan2,7, Gunnar Sørensen 3, Arne Mørk3, Pia Weikop 4, Ulrik Gether 5,
Benny Bang-Andersen 3,6✉, Lei Shi 2✉ & Claus J. Loland 1✉
The serotonin transporter (SERT) terminates serotonin signaling by rapid presynaptic reup-
take. SERT activity is modulated by antidepressants, e.g., S-citalopram and imipramine, to
alleviate symptoms of depression and anxiety. SERT crystal structures reveal two
S-citalopram binding pockets in the central binding (S1) site and the extracellular vestibule
(S2 site). In this study, our combined in vitro and in silico analysis indicates that the bound
S-citalopram or imipramine in S1 is allosterically coupled to the ligand binding to S2 through
altering protein conformations. Remarkably, SERT inhibitor Lu AF60097, the first high-affinity
S2-ligand reported and characterized here, allosterically couples the ligand binding to S1
through a similar mechanism. The SERT inhibition by Lu AF60097 is demonstrated by the
potentiated imipramine binding and increased hippocampal serotonin level in rats. Together,
we reveal a S1-S2 coupling mechanism that will facilitate rational design of high-affinity SERT
allosteric inhibitors.
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Serotonin (5-HT) transmission is involved in many basicbrain functions, such as regulation of mood, sleep, appetite,and sexual drive1. The serotonin transporter (SERT) is
embedded in the presynaptic membrane and terminates 5-HT
transmission by rapid reuptake of released 5-HT. SERT belongs,
together with the transporters for the neurotransmitters dopa-
mine, norepinephrine, γ-aminobutyric acid, and glycine, to the
family of neurotransmitter:sodium symporters (NSSs) that all
exploit the electrochemical potential stored in the Na+ gradient
to translocate substrates against their concentration gradients2–4.
Pharmacological inhibition of SERT is known to alleviate symp-
toms of depression and anxiety, the two most prevalent psychiatric
disorders ranking among the top five leading causes of disability
worldwide5,6. Specifically, the selective serotonin reuptake inhibi-
tors (SSRIs), such as S-citalopram (S-CIT) (Fig. 1a), sertraline and
paroxetine, are currently used to treat depression, anxiety,
obsessive-compulsive disorder (OCD), and post-traumatic stress
disorder (PTSD) among others7. The tricyclic antidepressants,
such as imipramine (IMI) (Fig. 1a) and amitriptyline, and the
multimodal antidepressants vilazodone and vortioxetine8, also
target SERT. In addition, SERT is in part targeted by (illicit)
psychostimulants such as MDMA (ecstasy), ibogaine, cocaine, and
amphetamine9,10.
The structures of human SERT11, drosophila dopamine
transporter12 and two bacterial NSSs, LeuT13 and MhsT14, have
revealed a conserved structural fold for NSSs with a primary
ligand binding (S1) site located in the center of the transmem-
brane domain. Interestingly, the existence of an allosteric binding
site in SERT was reported more than three decades ago15. The key
observation was that certain SERT inhibitors could impede the
dissociation of a pre-bound radiolabeled ligand16–19. The most
potent impedance being by S-CIT on [3H]S-CIT dissociation,
however, only displays a low potency (IC50 is ~5 µM), and in spite
of intensive investigations20,21 no other compound has shown to
possess higher potency20,22. Based on computational modeling
and experimental binding studies, we previously located the low-
affinity second binding site for S-CIT and clomipramine to the
extracellular vestibule (EV), the entry pathway toward the
S1 site21. Interestingly, in one of the recent hSERT crystal
structures (PDB 5I73), two S-CIT molecules are bound to the
protein: one in the S1 site (denoted as S1:S-CIT) and another
bound to a binding site in the EV—the S2 site (denoted as S2:S-
CIT) ~13 Å above the S1 site11,23. This is consistent with previous
findings that the EV of LeuT harbors a S2 site capable of binding
ligands24–26. The comparison of the 5I73 structure to the struc-
ture bound with only one S-CIT in S1 (PDB 5I71) shows that they
have identical conformations in the EV, and it is not clear whe-
ther ligand bindings in the S1 and S2 sites allosterically interact
with each other through modulation of any specific structural
motif27,28, which may result in conformational changes.
Allosteric modulators can potentially possess higher selectivity
due to the divergence of the binding sites among homologous
proteins29,30 resulting in fewer side effects. In addition, compared
with competitive inhibitors to the endogenous ligand, they may
retain some of the functions of the target proteins. Indeed, several
well-known allosteric modulators possess novel pharmacologic
properties such as use-dependency (e.g., lidocaine), or activity
modulation of the endogenous ligand (e.g., benzodiazepines), or
to perform asymmetric signaling as in metabotropic glutamate
receptor complexes31, all providing advantageous therapeutic
potentials over orthosteric modulators. For S-CIT, it has been
proposed that its allosteric binding in SERT contributes to its
higher efficacy and faster onset observed in clinical trials as
compared with racemic citalopram32–36. However, the low affi-
nity of S-CIT to S2 relative to S1 hampers the possibility to reveal
the specific therapeutic potentials in targeting this site. Thus, a
high affinity and selective S2-bound ligand would facilitate not
only a thorough mechanistic understanding of allosteric com-
munications between the S2 and S1 sites, but also a proper eva-
luation of the therapeutic potential of allosteric modulation
in SERT.
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Here, we provide mechanistic evidence for allosteric modula-
tions between the S1 and S2 sites in SERT by showing that the
effects of ligand binding to the S1 site allosterically propagate
through altered conformation of a structural motif between the S1
and S2 sites. In the context of these findings, we report the
identification and characterizations of a high-affinity S2-bound
inhibitor for SERT, Lu AF60097 ((S)-1-(4-fluorophenyl)-1-(3-(4-
(2-oxo-1,2-dihydroquinolin-7-yl)piperidin-1-yl)propyl)-1,3-dihy-
droisobenzofuran-5-carboxamide), in vitro, in silico, and in vivo.
Results
S1-binding is allosterically connected to S2-binding. We have
previously shown that the binding of either S-CIT or clomipra-
mine to the S2 site inhibits [3H]S-CIT dissociation from the
S1 site21. To examine whether ligand binding to S1 would induce
conformational changes of SERT that allosterically affect ligand
binding to S237, we first evaluated whether the inhibitory potency
of a S2-bound ligand can be differentially affected by the identity
of the S1-bound ligand. For S-CIT and IMI, we specifically
assumed that they would bind exclusively to S1 at nanomolar
concentrations (denoted as S1:S-CIT and S1:IMI). Accordingly,
we added 25 nM of either [3H]S-CIT or [3H]IMI to membranes
of COS-7 cells transiently expressing hSERT wild type (WT), and
then measured the dissociation rates of the two ligands in the
presence of increasing concentrations of S- or R-CIT (0.4 µM–1
mM) that should occupy the S2 site at high concentrations (S2:S-
CIT and S2:R-CIT). The increase in S2-occupancy by either S- or
R-CIT results in a dose-dependent inhibition of dissociation by
the S1-bound radioligand. The concentration of a S2-bound
ligand causing 50% decrease in the dissociation of a S1-bound
radioligand (IC50) is used as a measure to reflect the inhibitory
(allosteric) potency for S2 binding (see “Methods”). We found
that the allosteric potency of S2:S-CIT was 29-fold higher in the
presence of S1:[3H]S-CIT than in the presence of S1:[3H]IMI
(Fig. 1b, Table 1). In contrast, the allosteric potency of S2:R-CIT
was reversed, i.e., lower in the presence of S1:[3H]S-CIT relative
to S1:[3H]IMI (Fig. 1c, Table 1). The results indicate that the
allosteric potency of a S2-bound ligand is sensitive to the identity
of the S1-bound ligand. Thus, assuming no direct interaction
between the S1- and S2-bound ligands (see below), these results
support the idea that SERT conformational changes induced by
ligand binding to S1 modulate ligand binding to S2.
To probe the mechanistic details of a possible allosteric
interaction between ligands bound to S1 and S2, we performed
extensive molecular dynamics (MD) simulations at microsecond
scale using the ts3 and WT SERT models (see “Methods”) in
complexes with different combinations of S1- and S2-bound
ligands (Fig. 2, Supplementary Table 1). We first compared the
resulting conformations of the simulations in the presence of S1:
S-CIT without any ligand bound in S2 (denoted as S1:S-CIT/S2:
apo) to that of the 5I71 structure. When comparing the two
S-CIT bound SERT crystal structures, 5I71 and 5I73, we found
that the EV space occupied by the S2:S-CIT in 5I73 is filled by a
dodecane in 5I71 (likely part of a lipid molecule used in the
crystallization process) (Supplementary Fig. 1). Interestingly, in
the absence of any ligand in S2, our simulations in both ts3 and
WT constructs showed that the side chains of Phe334 and Phe335
of TM6 move toward the center of the EV and form an aromatic
cluster with Phe556 that rotates inward (Supplementary Fig. 1).
Consequently, Phe335 and Phe556 occupy the space that overlaps
with dodecane and S2:S-CIT in the crystal structures (Supple-
mentary Fig. 2). On the other hand, the resulting EV confor-
mations of the S1:S-CIT/S2:S-CIT simulations were similar to
that of the 5I73 structure. Thus, the conformational differences
observed between S1:S-CIT/S2:apo and S1:S-CIT/S2:S-CIT con-
ditions suggest that the binding of S-CIT in S2 is associated with
robust conformational rearrangements.
We then compared the SERT conformations in the S1:S-CIT/
S2:apo and S1:IMI/S2:apo conditions (Fig. 2b, d). We found that
different moieties of these two S1 ligands that face TM10, i.e., the
cyano group of S-CIT and the aromatic ring of IMI, have
significantly different impacts on the conformation of the bulge
helical turn in TM10 (Leu492 to Thr497). In particular, we found
a remarkable difference in the χ1 dihedral angle of Thr497
depending on the docked compound. The cyano group of S1:S-
CIT favors the χ1 rotamer of Thr497 to be in gauche−, while this
rotamer is more likely in gauche+ in the presence of S1:IMI
(Fig. 2g).
Next, we built and equilibrated SERT WT models in the S1:S-
CIT/S2:S-CIT and S1:IMI/S2:S-CIT conditions (see “Methods”,
Fig. 2c, e). The analysis of the MD simulations of these conditions
showed that the χ1 rotamer of Thr497 in the presence of S1:S-CIT is
further stabilized in gauche− by the addition of S2:S-CIT, whereas
the S2:S-CIT in the same pose is not stable in the presence of S1:
IMI, forcing Thr497 in the latter condition to rotate from gauche+
to the gauche− rotamer (Fig. 2f). When Thr497 is in gauche−, we
found that the S1-gating residue, Phe335, cannot form a stable
interaction with the benzofuran moiety of S2:S-CIT and transitions
between gauche− and trans rotamer in the presence of S1:IMI,
whereas this interaction is stable in the presence of S1:S-CIT. To
quantify this difference, we counted the numbers of transitions in
each condition, and found Phe335 transitions between gauche−
and trans rotamer at a rate of 145.4/µs in S1:IMI/S2:S-CIT, while
only 1.1/µs in S1:S-CIT/S2:S-CIT.
Thr497 and Phe335 are situated in between the S1 and S2 sites.
Their varied configurations in the S1:S-CIT/S2:S-CIT and S1:IMI/
S2:S-CIT conditions correlate with the conformation of Glu494,
which shows a higher propensity to form a salt bridge with the
Fig. 1 Experimental evidence for allosteric binding between the S1 and
S2 sites in SERT. a Chemical structure of the tested drugs. Left: imipramine
(IMI). Right: R(−)- and S(+)-citalopram (R-CIT and S-CIT, respectively).
b Allosteric potency of S-CIT measured as concentration-dependent
inhibition of either [3H]IMI or [3H]S-CIT dissociation, prebound to SERT
prior to the addition of S-CIT in the indicated concentrations. Data plotted as
inhibition of [3H]ligand dissociation rate by S-CIT relative to no S-CIT added
(ctrl). Prebound [3H]S-CIT (triangles) results in a 29-fold increase in S-CIT
allosteric potency relative to prebound [3H]IMI (circles), with IC50= 5.1
[4.6, 5.8] µM and 152 [125, 185] µM, respectively (mean [S.E. interval], n=
3). c Allosteric potency of R-CIT measured as in (b). Here R-CIT possesses a
fourfold higher allosteric potency for prebound [3H]IMI relative to prebound
[3H]S-CIT, with IC50= 5.3 [4.9; 5.8] µM and 21.5 [20.3; 22.7] µM,
respectively (mean [S.E. interval], n= 3–6). d Allosteric potency of S-CIT
(blue) and R-CIT (green) in SERT E494Q predicted to dissipate the allosteric
interaction between S1 and S2 sites. The allosteric potency is now collapsed
around the observed allosteric potency for S-CIT inhibition of [3H]IMI
dissociation (right dotted line) in SERT WT. The allosteric potency of S-CIT
(blue) for inhibition of [3H]S-CIT (triangles) and [3H]IMI (circles)
dissociation in E494Q is 64.8 [56.6; 74.1] µM and 131 [123; 140] µM,
respectively (mean [S.E. interval], n= 5–6). The same values for R-CIT are
137 [118; 158] µM and 199 [191; 207] µM, respectively (mean [S.E. interval],
n= 5). Left dotted line is allosteric potency for S-CIT with prebound [3H]
S-CIT from (b), shown for comparison. e Allosteric potency for S-CIT with
prebound [3H]S-CIT (triangles) or [3H]IMI (circles) in SERT T497A. Thr497
is predicted to mediate the S1:S2 allosteric interaction (see Fig. 2). The IC50
is collapsed, around the allosteric potency for [3H]S-CIT dissociation from
SERT WT (dotted lines); IC50 for S-CIT: 5.10 [3.20; 8.00] µM and 8.80
[5.90; 13.4] µM for inhibition of [3H]S-CIT and [3H]IMI dissociation,
respectively. The same values for R-CIT are 17.8 [15.7; 20.2] and 11.6
[10.1; 13.3], respectively (mean [S.E. interval], n= 3). Source data are
provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15292-y ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1491 | https://doi.org/10.1038/s41467-020-15292-y | www.nature.com/naturecommunications 3
charged N of S2:S-CIT in the presence of S1:S-CIT compared
with in the presence of S1:IMI (Fig. 2h), resulting in a more stable
pose in the former condition (Fig. 2i). Thus, we hypothesized that
the observed S2:S-CIT affinity difference in these two conditions
(Fig. 1b) is likely resulted from the different impacts of S1-bound
ligands on the interaction between S2:S-CIT and Glu494, which
are mediated by the Thr497-Phe335 motif.
To experimentally test this hypothesis, we removed the
negative charge of Glu494 by the E494Q mutation and measured
the allosteric potency of R- and S-CIT in the presence of S1:[3H]
S-CIT or [3H]IMI (Fig. 1d). Remarkably, compared with WT, in
hSERT E494Q, the allosteric potency of S2:S-CIT was sig-
nificantly reduced for S1:[3H]S-CIT but did not change for [3H]
IMI, and the two potencies became virtually the same. The same
was observed for S2:R-CIT (Fig. 1d, Supplementary Table 2). As
our simulation results suggest that Thr497 and Phe335 are
sterically crowded in the S1:IMI/S2:S-CIT condition, we further
hypothesized that by mutating Thr497 to a residue with a
smaller sidechain, the space in between S1 and S2 would be less
crowded, which might facilitate the S2:S-CIT binding. Indeed, in
the presence of [3H]IMI, the allosteric potency of S2:S-CIT was
increased 17-fold in SERT T497A relative to SERT WT. In
contrast, the allosteric potency of S2:S-CIT or S2:R-CIT in the
presence of [3H]S-CIT was not affected by T497A (Fig. 1e,
Supplementary Table 2). Taken together, we propose that
Thr497-Phe335 represents a structural motif mediating allos-
teric communication between the S1 and S2 sites.
Identification of a high affinity S2 inhibitor. Based on these
findings, we hypothesized that the binding of S2-ligands having
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Fig. 2 MD simulations of the allosteric interaction between SERT S1 and S1 sites. In the presence of S1:S-CIT the Thr497 χ1 dihedral is mostly shifted
towards gauche−, whereas in the presence of S1:IMI, it is in gauche+, which in turn affects the salt bridge interaction between S2:S-CIT and Glu494. In all
panels, the S1:S-CIT conditions are colored in salmon, whereas the S1:IMI conditions are in purple. a A zoomed-out view of the 5I73 structure showing the
S1 and S2 sites. b A zoomed-in view of the equilibrated model of WT S1:S-CIT/S2:apo, c S1:S-CIT/S2:S-CIT, d S1:IMI/S2:apo, and e S1:IMI/S2:S-CIT.
g Distribution of the Thr497 χ1 rotamer for S1:S-CIT/S2:apo, S1:IMI/S2:apo (dotted lines), and S1:S-CIT/S2:S-CIT and S1:IMI/S2:S-CIT (solid lines)
conditions. h Distribution of the Glu494/S2:S-CIT distance (minimum distance between the charged N of S2:S-CIT and the two carboxyl oxygens of
Glu494) for S1:S-CIT/S2:S-CIT and S1:IMI/S2:S-CIT conditions. i S2:S-CIT is more stable in the presence of S1:S-CIT (salmon) than in the presence of S1:
IMI (purple) measured by pairwise ligand RMSDs (see “Methods”).
Table 1 S1 affinity and allosteric potency of investigated compounds to SERT WT.
Compound Inhibition of [3H]S-CIT binding
(IC50 in nM)
n Allosteric potency inhibition of [3H]S-CIT
dissociation (IC50 in nM)
n Allosteric potency inhibition of [3H]IMI
dissociation (IC50 in nM)
n
S-citalopram 5.4 [5.1; 5.7] 6 5200 [4600; 5800] 3 152000 [125000; 185000] 3
R-citalopram 180 [150; 210] 7 21500 [20300; 22700] 6 5340 [4880; 5830] 3
Lu AF60097 270 [200; 360] 6 6500 [5070; 8310] 4 31 [25; 39] 6
AE 1040 [900; 1200] 3 33800 [30700; 37300] 3 120 [100; 140] 4
AF 79 [61; 102] 4 10400 [8450; 12900] 5 190 [170; 220] 3
Data for [3H]S-CIT binding inhibition are obtained by non-linear regression analysis of competition binding experiments between [3H]S-CIT and increasing concentrations of the indicated compound (10
concentrations in triplicates). Allosteric potencies are the IC50 from non-linear regression analysis of the change in dissociation rate constant relative to no compound present (k[cmpd]/kbuffer) as a
function of the added compound concentration (Log[cmpd]). Experiments performed on membrane preparations of COS-7 cells expressing SERT WT. Data are shown as mean [SE interval] and are
calculated from pIC50 and the SE interval from pIC50 ± SE.
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higher allosteric potency in the presence of S1:IMI must not result
in steric crowdedness near the Thr497-Phe335 motif, while
forming a favored interaction with Glu494. To further char-
acterize the potential of the S2 site as a druggable allosteric
site28,31 with the ultimate goal of developing therapeutic agents
against it, we screened a compound library of citalopram analogs
and assessed their allosteric potency using both S1:[3H]S-CIT and
S1:[3H]IMI as described above.
Strikingly, we found three S-CIT analogues possessing very
potent (30–200 nM) inhibition of the S1:[3H]IMI dissociation,
but low (6–30 µM) allosteric potency on inhibiting the S1:[3H]S-
CIT dissociation (Fig. 3a–c, Table 1). Interestingly, these three
compounds all have a carboxamide instead of the cyano group on
the benzofuran moiety of the S-CIT scaffold. They differ,
however, in the presence and position of double bonds in the
bicyclic N-substituents (Fig. 3a). In particular, the allosteric
potency of Lu AF60097 in the presence of S1:IMI was 31 nM
(Table 1), which is more than a 150-fold increase compared with
citalopram.
To understand the molecular mechanism of the selective high
allosteric potency of Lu AF60097, we characterized and compared
the binding modes of S2:Lu AF60097 in the presence of S1:S-CIT
versus S1:IMI by MD simulations. We first docked Lu AF60097
unbiasedly into the extracellular vestibule of our equilibrated S1:
IMI/S2:apo model, and identified three poses (denoted as pose
“I”, “II”, and “core”) to be further relaxed and evaluated by MD
simulations (see “Methods” and Supplementary Table 1). We
then carried out molecular mechanics/generalized Born surface
area (MM/GBSA) calculations to evaluate the binding energy of
the equilibrated poses, and found that the pose “core”, in which
the S-CIT scaffold of Lu AF60097 adopts a similar orientation
as S2:S-CIT in the S2 site, has the most favored energy (pose
“I”, −59.7 kcal/mol; pose “II”, −73.7 kcal/mol; pose “core”,
−77.6 kcal/mol). Consistent with the predicted binding free
energy, the S-CIT core of Lu AF60097 in pose “I” protrudes out
of the EV and is not fully engaged with hSERT, resulting in
drastically weaker binding (Supplementary Fig. 3a). Whereas
pose “core” forms the ionic interaction with Glu494 and is in
proximity to Lys490, pose “II” does not form interactions with
either of these residues but a polar interaction with Asp328
(Supplementary Fig. 3b, c). Therefore, we chose the pose “core”
for further analysis (Fig. 3d, e). Our mutagenesis results of
Asp328, Lys490, and Glu494 indeed support pose “core” but
not pose “II” (see below).
Our MD simulations show that the cyano-to-carboxamide
substitution orients the benzofuran moiety of Lu AF60097 to
move slightly away from the Thr497-Phe335 motif compared
with S2:S-CIT: whereas the cyano group of S2:S-CIT points to a
polar cavity under Gln332, the carbamoyl group of Lu AF60097
forms a H-bond to the sidechain of Gln332 (Supplementary
Fig. 4). Such a rearrangement allows the sidechain of Thr497 to
be in the preferred gauche+ χ1 rotamer in the presence S1:IMI,
while S2:Lu AF60097 forms a salt bridge with Glu494 through its
charged N (Fig. 3f, g). In addition, the quinolinone moiety of Lu
AF60097 protrudes into a sub-pocket near the tip of the
extracellular loop 4b (EL4b) with the 2-oxo modification forming
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Data are shown as means ± SEM (error bars). Source data are provided as a Source Data file.
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a hydrogen bond (H-bond) with Ser404 in EL4b (Fig. 3d and
Supplementary Movie 1 and 2). Thus, the stability of this pose is
likely associated with the structural integrity of EL4b and nearby
interacting segments. Accordingly, mutations in EL4b and in
neighboring TM3 are expected to destabilize this pose and reduce
the binding affinity of S2:Lu AF60097 (see below).
Interestingly, when similar MD simulations were carried out for
a S1:S-CIT/S2:Lu AF60097 model (Fig. 3e), in which the S-CIT
scaffold of Lu AF60097 is aligned to S2:S-CIT as in the pose “core”,
S2:Lu AF60097 could not form the salt bridge with Glu494 through
its charged N (Fig. 3g), while its quinolinone moiety could not get
into the sub-pocket near EL4b. These divergent poses of S-CIT
scaffolds of S2:Lu AF60097 versus S2:S-CIT are likely associated
with the replacement of cyano group with a carboxamide in the
benzofuran moiety. Consequently, the ionic interaction of S2:Lu
AF60097 to Glu494 is much weaker than that of S2:CIT in the
presence of S1:S-CIT (Figs. 2h and 3g). Moreover, by comparing
the MD frames from both the S1:IMI/S2:Lu AF60097 and S1:S-
CIT/S2:Lu AF60097 conditions when the quinolone moiety of Lu
AF60097 did not protrude into the sub-pocket near EL4b, we
found that the moiety is in different orientations and dynamics in
the EV (Supplementary Fig. 5). Together, our computational
results indicate that the allosteric interactions between the different
S1:ligands and S2:Lu AF60097 result in markedly different poses of
S2:Lu AF60097, which could account for the observed 200-fold loss
in IC50 in the presence of S1:[3H]S-CIT compared with that in the
presence of S1:[3H]IMI (Table 1).
The S2:Lu AF60097 binding mode is validated by S2 mutants.
From the analysis of equilibrated binding mode of S2:Lu AF60097
in the presence of S1:IMI, we identified residues from TMs 1, 6,
10, 11, EL2, and EL4 that directly interact with Lu AF60097
(Fig. 4a and Supplementary Table 3). To validate this prediction
experimentally, we mutated individually or in combination a set
of representative residues in TMs 1 (R104K), 3 (I179F), 6 (D328N
and A331D), 10 (A486E-K490A and E494K/Q), 11 (F556R/L),
and EL4 (L406E). All the SERT mutants are able to bind and
transport [3H]5-HT when expressed in COS7 cells (Table 2).
In the [3H]IMI dissociation assay, we found in agreement with
the MD simulations that most mutations decreased the allosteric
potency of Lu AF60097 more than tenfold (Fig. 4b, Table 2). The
F556R mutant caused the most significant change with a complete
ablation of the allosteric potency within the concentration range of
the applied Lu AF60097. According to our MD simulations, Phe556
has a stable aromatic interaction with the fluorophenyl ring of the S-
CIT scaffold in Lu AF60097, and therefore the F556R mutation
would expectedly cause a drastic change in the IC50. Ala331 interacts
with both of the aromatic rings in the S-CIT scaffold of Lu AF60097
in the MD simulations, and the substitution with the negatively
charged Asp residue does indeed cause a ~300-fold decrease in
allosteric potency, suggesting a critical position of this residue in the
binding pocket for S2:Lu AF60097. In addition, mutations L406E in
EL4b and I179F in neighboring TM3 are expected to disrupt the
structural integrity of EL4b, a segment predicted in accommodating
the quinolinone moiety of Lu AF60097. Indeed, these mutations
resulted in 21- and 14-fold decrease in the allosteric potency of S2:
Lu AF60097, respectively. Taken together, most of the mutations
based on the predicted pose “core” from our MD simulations have
detrimental effects on Lu AF60097 binding in vitro, suggesting that
the compound does bind to the predicted S2 site. Of note, E494Q
only resulted in a ~5-fold decrease in allosteric potency. This is in
contrast to the S1:S-CIT/S2:S-CIT condition in which the mutation
caused a ~12-fold decrease. The difference is likely due to a reduced
contribution from the salt bridge to binding affinity for the larger Lu
AF60097 (39 heavy atoms, compared 24 of S-CIT). In our
equilibrated S1:IMI/S2:Lu AF60097 model from the MD simula-
tions, Lu AF60097 in pose “core” interacts with the backbone but
not the sidechain of Asp328. Thus, the only minor (~2-fold)
decrease in allosteric potency caused by the D328N mutation was
expected. This result also argues that Lu AF60097 is less likely to be
in pose “II”, which forms a polar interaction with the sidechain of
Asp328 (Supplementary Fig. 3b).
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Competitive and non-competitive inhibition of 5-HT trans-
port. Because of the low potency of S2:Lu AF60097 in inhibiting
the dissociation of S1:[3H]S-CIT, we reasoned that it was possible
to assess the affinity of Lu AF60097 at the S1 site using [3H]S-CIT
equilibrium binding. The results of such experiments showed that
the IC50 of Lu AF60097 was 265 [196; 358] nM (mean [S.E.
interval], n= 6, Table 1, Supplementary Fig. 6). Whereas we
cannot rule out that [3H]S-CIT binding is partially modulated by
the allosteric interaction, the results suggest that the S2 (in the
presence of S1:IMI) over S1 selectivity for Lu AF60097 is at least
eightfold. For S-CIT, the selectivity is ~1000-fold in favor of the
S1 site. In comparison, when we performed a binding experiment
under similar conditions but using [3H]IMI as the radioligand,
[3H]IMI was not displaced by Lu AF60097, possibly because Lu
AF60097 has a high S2 affinity in the presence of S1:IMI and
locks [3H]IMI in the S1 site (Supplementary Fig. 6). This finding
further substantiates the ligand-dependent differences in the
allosteric interaction between the S1-and S2-bound ligands.
Next, we investigated the capability of Lu AF60097 to inhibit
the transport of [3H]5-HT by hSERT expressed in COS-7 cells
(Fig. 5). Lu AF60097 inhibited [3H]5-HT uptake with an IC50 of
207 [202; 214] nM (mean [S.E. interval], n= 5, Fig. 5a). This IC50
is different from its measured allosteric potency but similar to the
equilibrium binding affinity for Lu AF60097 when displacing
[3H]S-CIT, suggesting a S1 component of Lu AF60097’s
inhibition of the uptake. To further substantiate the possibility
of a S1-binding component, we also performed [3H]5-HT uptake
inhibition in the F556R mutant, which only showed very minimal
allosteric binding by Lu AF60097 (Fig. 4). Indeed, the uptake
inhibition by Lu AF60097 in this mutant was not different from
WT (Ki= 220 [190; 240] and 260 [210; 310] nM, n= 15 and 3,
for WT and F556R, respectively, Fig. 5a).
To examine whether the inhibition of 5-HT uptake is due to a
blockade by a competitive or a non-competitive action by Lu
AF60097, we performed [3H]5-HT saturation uptake with
increasing concentrations of Lu AF60097 (Fig. 5b, Supplementary
Table 4). The results show that Lu AF60097 inhibits 5-HT uptake
mainly by changing the KM of [3H]5-HT transport in the low
concentrations, indicative of a competitive action. In the high
concentrations Lu AF60097 also reduce the maximal uptake
velocity (VMAX), suggesting a combined competitive and non-
competitive mechanism. Thus, together with the [3H]S-CIT
equilibrium binding results, we found that Lu AF60097 possesses
a S1-binding-based competitive component as well, when the
S1 site is not occupied by IMI.
In our prolonged MD simulations of the potential binding pose
of Lu AF60097 in the S1 site, we found that its S-CIT scaffold
adopts a similar pose as that of the S1-bound S-CIT, while the
quinolinone moiety protrudes out of the S1 site. However, its
positively charged tertiary amine moiety cannot form any ionic
interaction with either the sidechain carboxyl group of Asp98 or
the backbone carbonyl group of Tyr95 (Supplementary Fig. 7)38.
This less favored binding mode of Lu AF60097 is consistent with
its significantly reduced affinity at S1 compared with S1:S-CIT
(Table 1).
Lu AF60097 and imipramine can block SERT synergistically.
Since the Lu AF60097 affinity is markedly increased in the pre-
sence of S1:IMI, we predicted that they would inhibit 5-HT
uptake synergistically, i.e., the inhibitory effect of applying them
together would be more potent than combining the effects of
applying them individually. Thus, we studied the inhibition of
[3H]5-HT uptake by low concentrations of either IMI or Lu
AF60097 alone or in combination. As shown in Fig. 5c, IMI
(4 nM) or Lu AF60097 (27 nM) alone only resulted in a modest
decrease in [3H]5-HT uptake (10.7 ± 0.8% and 5.0 ± 1.8% inhi-
bition, respectively, relative to control, mean ± S.E., n= 5–7). In
contrast, the two compounds together acted synergistically and
caused a significant 36.2 ± 0.3% decrease of the 5-HT uptake
(mean ± S.E., n= 5). The results support that the binding of one
ligand facilitates the binding of the other ligand.
Hippocampal 5-HT levels are increased by Lu AF60097. To
investigate whether Lu AF60097 administration has any effect on
5-HT homeostasis in an in vivo setting, we performed micro-
dialysis in rat hippocampus with local administration of Lu
AF60097. Two microdialysis probes were inserted, one in each
hemisphere, into rat hippocampus. In close vicinity of each probe,
an injection needle was placed and 5-HT levels were measured
through the microdialysis probe on the freely moving rats. When
5-HT levels were stabilized, we injected 1 µl of 250 nM Lu
AF60097 in one hemisphere while saline (artificial cerebrospinal
fluid, aCSF) was injected in the other for comparison. Lu
AF60097 increased 5-HT levels reaching significance after 80 min
and reached to about 6-fold above saline after 2 h (Fig. 6a). The
Table 2 Effect of Lu AF60097 in inhibiting [3H]IMI dissociation from SERT WT and mutants.
SERT construct VMAX [3H]5-HT (fmol/min/105c) KM (5-HT) (nM) n Lu AF60097 allosteric
potency (nM)
n ΔAP (mut/WT)
SERT WT 4540 ± 740 520 [460;600] 21 31 [25; 39] 6 –
R104K (TM1) 480 ± 80 1100 [1000;1200] 3 630 [460; 850] 4 19
I179F (TM3) 1030 ± 430 2000 [1600;2400] 3 440 [270; 710] 5 14
D328N (TM6) 11300 ± 2200 1400 [970;1900] 6 54 [45; 65] 4 1.7
A331D (TM6) 5073 ± 418 290 [250; 330] 3 9100 [9000; 9200] 3 293
L406E (EL4) 114 ± 38 300 [280;320] 5 650 [610; 700] 5 21
A486E (TM10) 800 ± 140 320 [250;400] 6 470 [390; 560] 5 15
A486E-K490A 410 ± 140 190 [83;420] 2 2400 [2100; 2700] 3 77
E494K (TM10) 4700 ± 850 1400 [1200;1700] 4 8900 [7500; 10500] 3 286
E494Q TM10) 17100 ± 400 3900 [1900; 7700] 2 170 [150; 180] 3 5
F556L (TM11) 8300 ± 2000 1300 [1200; 1500] 4 330 [310; 340] 3 10
F556R (TM11 9400 ± 1680 920 [700; 1200] 7 >10000 3 >300
Characterization of [3H]5-HT transport and binding capacities for SERT WT and the investigated mutants (domain location in parentheses). 5-HT transport is performed on intact COS7 cells transiently
expressing the indicated SERT construct. VMAX and KM for 5-HT is calculated based on the IC50 and catalytic activity as described in Methods. Allosteric potencies are the IC50 from non-linear regression
analysis of the change in dissociation rate constant of [3H]IMI relative to no Lu AF60097 present (k[Lu AF60097]/kbuffer) as a function of the added concentration (Log[Lu AF60097]). Allosteric potency
experiments are performed on membrane preparations of COS-7 cells expressing SERT WT. Data are shown as mean and either ± SE (for VMAX) or [SE interval] and are calculated from pIC50 and the SE
interval from pIC50 ± SE. Note that value for SERT WT is the same data set as shown in Table 1. ΔAP (mut/WT), change in allosteric potency for mutants relative to SERT WT.
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results suggest that Lu AF60097 is capable of targeting and
blocking SERT function in vivo at a concentration no higher than
250 nM. We further assessed whether it was possible to mimic the
synergistic effect on 5-HT levels we observed on cell lines when
co-administering IMI and Lu AF60097. To match the con-
centrations from the in vitro experiment, we first performed an
in vitro recovery experiment to determine the fraction of com-
pounds, which would perfuse through the dialysis probe. We
found that 18.6 ± 1.1% and 3.22 ± 0.7 (means ± SEM, n= 3) of
IMI and Lu AF60097, respectively would cross the probe mem-
brane. Based on these experiments, we found that the perfusion of
either 0.36 µM IMI or 1.9 µM Lu AF60097 in the microdialysis
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Fig. 5 Pharmacologic properties of Lu AF60097 binding to SERT. a
Inhibition of [3H]5-HT uptake by Lu AF60097 in SERT WT and F556R.
Intact COS-7 cells were pre-incubated with Lu AF60097 for 15 min before
[3H]5-HT uptake was initiated. b Lu AF60097 inhibits [3H]5-HT uptake
with a mixture of competitive and non-competitive mechanisms. Saturation
uptake experiments for [3H]5-HT transport as a function of increasing Lu
AF60097 concentrations (0–640 nM). The VMAX decreases with
increasing Lu AF60097 (from 1180 ± 20 fmol/min (no Lu AF60097) to
920 ± 20 fmol/min (640 nM Lu AF60097). In addition, the KM-value for 5-
HT increases with increasing concentration of Lu AF60097 (KM= 484 nM
and 1650 nM for buffer only and 640 nM Lu AF60097, respectively
(Supplementary Table 4). c Application of Lu AF60097 and imipramine
together inhibits [3H]5-HT uptake synergistically. Imipramine (4 nM) and
Lu AF60097 (27 nM) results in a minor inhibition of [3H]5-HT uptake (to
89.3 ± 0.8 and 94 ± 2% of control, respectively). In contrast, adding the
same concentration of the two compounds together results in a
significantly higher decrease of [3H]5-HT uptake (64.8 ± 0.3%). ****p <
0.001 relative to addition of either imipramine or Lu AF60097 alone (one-
way ANOVA with Tukey’s multiple comparisons test). All experiments are
performed on intact COS-7 cells transiently transfected with SERT WT.
Data are shown as means ± SEM (error bars) of at least three experiments
performed in triplicates. Source data are provided as a Source Data file.
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Fig. 6 Effects of Lu AF60097 and imipramine on 5-HT levels in rat
hippocampus. a Changes in extracellular 5-HT levels after injection (dotted
line) of 1 µl (250 nM) Lu AF60097 (squares) or saline (circle) in ventral
hippocampus of freely moving rats. The 5-HT levels show a continuous
increase at all time points after the 40min post injection bin to a maximum
of 602 ± 156% of basal level (data are means ± S.E.M., n= 6). b
Hippocampal perfusion of Lu AF60097 and imipramine synergistically
increases extracellular 5-HT levels. Extracellular 5-HT levels were
determined 40min prior and 160min after initiating (dotted line) a
continuous perfusion of either saline (aCSF, circles), 1.9 µM Lu AF60097
(closed squares), 0.36 µM imipramine (open squares), 1.9 µM Lu AF60097
+ 0.36 µM imipramine (triangles) in ventral hippocampus of freely moving
rats. Inset: Area under the curve during perfusion (20–160min) for the four
conditions (matching colors to curves in main figure). The released 5-HT
when perfused with both imipramine and Lu AF60097 is significantly
increased (green bar). When perfused with either of the compounds alone
(blue bars), the 5-HT levels are not different form saline (black bar). Data
are means ± SEM (error bars), n= 9–15. The extracellular concentrations of
5-HT in both (a) and (b) are assessed by microdialysis and expressed as
the percentage of the basal levels in the three fractions collected prior to
perfusion start (dotted line). **P < 0.01, ***P < 0.001 vs. saline; ¤P < 0.05, ¤
¤P < 0.01, ¤¤¤P < 0.001 vs. Lu AF60097; #P < 0.05, ##P < 0.01, ###P < 0.01
vs. imipramine; Bonferroni post-hoc test after significant RM two-way
ANOVA or one-way ANOVA. Source data are provided as a Source
Data file.
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probe had no effect on hippocampal 5-HT levels relative to saline
within the duration of the experiment (Fig. 6b). In contrast, when
the two compounds were administered together, the 5-HT levels
rose to significantly higher levels either 40 or 60 min after per-
fusion start, relative to IMI and Lu AF60097 alone, respectively.
The increased 5-HT levels remained increased during the
remaining of the 160 min test period. These data suggests that Lu
AF60097 is also able to potentiate the effect of IMI on extra-
cellular 5-HT levels in an in vivo setting.
Discussion
The presence of an allosteric site in SERT has been known for
more than three decades39. Structurally diverse compounds such
as sertraline17, paroxetine19, clomipramine21, and citalopram21
have been shown to possess allosteric activity as they can impair
dissociation of a pre-bound high affinity radioligand to the
transporter. However, the allosteric potencies of these compounds
are all in the micromolar range, while they bind to the orthosteric
site with low-nanomolar affinity. Accordingly, it has not been
possible to isolate their specific allosteric impact on SERT func-
tion. Mutagenesis studies21 and x-ray crystallography11 have
located the allosteric site to the EV of the transporter. In addition
to SERT, allosteric sites at similar locations have been found in
NET18 and LeuT26. Further, it has been proposed that S2 occu-
pancy by a substrate in LeuT is required for substrate to be
released from S124, while the substrate 5-HT has been shown to
have an allosteric effect on [3H]IMI dissociation in SERT, though
with low potency39.
Here, we show at atomistic detail that the S1 and S2 binding
sites in SERT are allosterically coupled to each other. By com-
bining extensive (~125 µs) MD simulations of various conditions
and site-directed mutagenesis, we show that the impact of ligand
binding to the S1 site propagates through the Thr497-Phe335
motif to alter the configuration of the S2 site. In particular, the
propensity of Glu494 in the S2 site to form a salt bridge with the
S2-bound ligands is differentially affected by S1:S-CIT and S1:
IMI. Consistent with this prediction, removal of the negative
charge of Glu494 (E494Q) results in similar S2 affinities for S-CIT
in the presence of either S1:IMI or S1:S-CIT, while the same
impact on the S2 affinities of R-CIT were observed as well (Fig. 1).
Moreover, mutating Thr497 to a residue with a smaller sidechain
(T497A) improves S2:S-CIT binding in the presence of S1:[3H]
IMI, to the same extent as when [3H]S-CIT is bound to S1.
Together, the results suggest that the configuration of the Thr497-
Phe335 motif is sensitive to the identity of the S1-bound ligand
and plays a critical role in the allosteric communication between
the S1 and S2 sites.
We further report on a compound with nanomolar affinity at
the S2 site of hSERT. Lu AF60097 has a >100-fold gain in
allosteric potency relative to any other reported S2-bound hSERT
ligand22. Our MD simulations suggest that Lu AF60097 can
stably bind in the EV with its S-CIT scaffold in a similar pose as
that of S2:S-CIT revealed by the hSERT crystal structure11.
Interestingly, the potency of Lu AF60097 in the S2 site shows a
reversed trend compared with S2:S-CIT, i.e. higher allosteric
potency with S1:[3H]IMI than with S1:[3H]S-CIT (Fig. 3b, c).
Based on our simulation results, we propose that, compared with
S2:S-CIT, the carboxamide substituent of Lu AF60097 alters the
polar interactions near Gln332 and shifts the S-CIT scaffold
slightly away from the Thr497-Phe335 motif thus relieving the
steric crowdedness between the S1 and S2 sites in the presence of
S1:IMI. In addition, our simulation results indicate that the
selectively improved S2:Lu AF60097 affinity in the presence S1:
IMI may also come from the specific binding of the quinolinone
substituent of Lu AF60097 in a sub-pocket near EL4, which is not
formed in the presence of S1:S-CIT. Mutations of selected resi-
dues show detrimental effects on Lu AF60097 allosteric potency,
supporting its predicted binding pose. Taken together, we con-
clude that, in the presence of S1:IMI, Lu AF60097 binds with high
affinity to the EV of SERT.
In addition to high S2 affinity, high S2 specificity is also
necessary to isolate the allosteric impact of a S2-bound ligand on
SERT function. Thus, we investigated whether Lu AF60097 has
any S1 binding component and found that it binds at S1 with an
IC50 of ~ 265 nM (Supplementary Fig. 6). This value is ~9-fold
higher than that of its allosteric potency and is promising for
isolating the allosteric impact. Supported by the [3H]5-HT
saturation uptake experiment (Fig. 5b) and the F556R mutation,
which virtually eliminates S2:Lu AF60097 binding, but has no
impact on its inhibition of the 5-HT uptake, we conclude that Lu
AF60097 has a S1 binding component.
Whereas we present the first lead compound with high-affinity
allosteric association to SERT in vitro, an immediate question is
whether this translates into an in vivo setting. We showed that a
small amount of Lu AF60097 (1 µl 250 nM) is able to elicit a
marked increase of extracellular 5-HT levels in the microdialysis
analysis, suggesting that the compound is also capable of target-
ing SERT in vivo. This we further substantiated by showing that
co-administration of IMI and Lu AF60097 in vitro (Fig. 5c) and
in vivo (Fig. 6b) does have a potent effect on the inhibition of 5-
HT uptake, compared with administrating either of these two
compounds alone in the same concentrations. This opens the
door for further in vivo analysis of Lu AF60097 or similar next
generation compounds to adequately assess these potentials. We
propose that a clinical potential of the allosteric inhibitor prop-
erty of Lu AF60097 lies in its potentiation of IMI binding. This
might make it possible to lower the therapeutic dose of IMI by co-
administering an allosteric binder such as Lu AF60097, preser-
ving the positive effects of tricyclic antidepressants on major
depressions while reducing the detrimental side effects such as
cardiac arrhythmias and -arrest40 and interferences with auto-
nomic control41. Indeed, the results herein open the possibility of
performing additional in vivo experiments with SERT allosteric
inhibitors in combination with current effective orthosteric
inhibitors, to probe for improved therapeutic effects using
behavioral paradigms for depression or anxiety.
Methods
Site directed mutagenesis. The human SERT was cloned into the pUbi1z vector
using the NotI and XbaI. Mutations herein were generated using the QuickChange
method (adapted from Stratagene, La Jolla, CA) or ordered through GeneArt. All
mutations were confirmed by DNA sequencing. The used primers were
L406E, CGCAGGTCCCAGCCTCGAGTTCATCACGTATGCAG
A486E, CTTTTGGAGGGGAGTACGTGGTGAAG
E494K, GAAGCTGCTGGAGAAGTACGCCACGGGG
F556L, CATTTGCAGTTTACTCATGAGCCCGCCAC
F556R, CATCATTTGCAGTAGACTGATGAGCCCG
Only the sense primers are shown. The complimentary antisense primers were
also used.
Transfection and Membrane preparation. Membranes were prepared from COS-
7 cells (a generous gift form Prof. U Gether, U. of Copenhagen, DK), after they
were transient transfected with hSERT WT or mutants using the Lipo2000
transfection protocol (Invitrogen): 2 µg SERT plasmid and 6 µL Lipofectamine were
mixed each with 250 µL Opti-MemR(1×) and incubated for 20 min for micelle
formation. The mixture was added to 10 ml DMEM 1885 medium containing 4
million COS-7 cells. After 5 h, 25 ml DMEM1885 with antibiotic was added. After
48 h. the cells were harvested with PBS+ 5 mM EDTA, washed, and lysed with 1
ultrasound burst (Branson Sonifier with microtip) in membrane buffer (120 mM
NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.2 mM CaCl2, 25 mM HEPES, pH 7.4).
Membranes were pelleted at 4900 × g and resuspended in membrane buffer con-
taining 0.3 M sucrose and stored at −80 °C until used.
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[3H]IMI and [3H]S-CIT dissociation rate assay 25 nM [3H]IMI (40–50 Ci/
mmol) or [3H]S-CIT (85 Ci/mmol) were added to membranes incubated for
30 min at 0 °C. Dissociation was initiated by 12× dilution of membrane aliquots
with membrane buffer containing 0.1 µM paroxetine and the indicated
concentrations of allosteric inhibitor. Note: 0.1 µM paroxetine has no allosteric
effect on the dissociation of [3H]IMI and [3H]S-CIT. The dissociation was assessed
at seven time points (5–10–15–20–30–50–70 min) and stopped by rapid filtration
of the samples through GF/B filters using a Tomtec cell harvester and washed for
20 s with ice-cold 0.2 M NaCl. Experiments were performed in a water bath at a
temperature where t½ for control dissociation (i.e. dissociation without drug) were
set to ~15 min. All experiments were performed in at least three independent
experiments.
[3H]S-CIT and [3H]IMI competitive binding experiments were performed on
membrane preparations of COS-7 cells transiently transfected with SERT WT.
Membrane aliquots were mixed with membrane buffer containing 5–10 nM of
either [3H]S-CIT or [3H]IMI and Lu AF60097 in the indicated concentrations to a
final volume of 300 µL. The binding experiments were incubated 1 h at room
temperature and subsequently filtered, washed and counted as described under
‘[3H]IMI and [3H]S-CIT dissociation rate assay’. Non-specific binding was
determined by adding 5 µM paroxetine.
[3H]5-HT uptake experiments were performed using 5-[1,2-3H]
hydroxytryptamine (25–30 Ci/mmol). COS-7 cells, transfected with SERT WT or
SERT mutants were seeded in 24-well dishes (105 cells/well) coated with poly-
ornithine. The seeded cell number were adjusted to achieve an uptake level of
maximally 10% of total added [3H]5-HT. The uptake assays were carried out 2 days
after transfection. Prior to the experiments the cells were washed once in 800 µL
uptake buffer (120 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.2 mM CaCl2, 10 mM
glucose, 25 mM HEPES, pH 7.4) at room temperature. Drugs tested for inhibition
of uptake were added to cells in indicated concentrations 30 min prior to addition
of 0.3 µCi [3H]5-HT. After incubating 3 min (WT) or 5 min (mutants) the cells
were washed twice with 500 µL ice-cold uptake buffer, lysed in 250 µL of 1% SDS
and left for 1 h at 37 °C. All samples were transferred to 24-well counting plates,
and 500 µL Opti-phase Hi Safe 3 scintillation fluid was added followed by counting
in a Wallac Tri-Lux beta-scintillation counter. Nonspecific uptake was determined
in the presence of 1 µM paroxetine. All determinations were performed in
triplicate.
Molecular docking. We used the crystal structures of hSERT bound with S-
citalopram in the S1 site only (PDB ID 5I71), and bound in both S1 and S2 sites
(PDB ID 5I73) in ts3 construct as the starting points for our modeling studies. The
binding site ions missing in the crystal structures were added. For the WT hSERT
models, the three thermostabilizing mutations that were introduced in the ts3
construct were mutated back to the WT residues.
Imipramine was docked into the S1 site using the induced-fit docking (IFD)
protocol42 implemented in the Schrodinger suite (release 2016-4). The best-scoring
pose was selected, which is consistent with previously deduced imipramine binding
pose43.
Lu AF60097 was docked into the S2 site using the IFD protocol. The RMSD
values of the ensemble of IFD poses were calculated and clustered using the
centroid linkage method as implemented in the Conformer Cluster module of
Maestro software (release 2016-4, Schrodinger Inc., New York, NY). Three largest
clusters of Lu AF60097 poses were: pose I, where dihydroisobenzofuran moiety is
close to Phe556 and fluorophenyl is close to TM1b and TM6; pose II, where
fluorophenyl is close to Phe556 and dihydroisobenzofuran moiety is close to TM1b
and TM6; and pose “core”, where the benzodioxo and fluorophenyl moieties of the
S-CIT scaffold adopt a similar orientation as S2:S-CIT (PDB ID 5I73) and the
quinolinone moiety of Lu AF60097 protrudes toward extracellular milieu. These
three poses were selected as initial starting points for further relaxation by MD
simulations (Supplementary Table 1) and evaluation by MM/GBSA for their
binding energy (see below).
MM/GBSA analysis. The Molecular mechanics/generalized Born surface area
calculations (MM/GBSA) analysis of the S1:IMI/S2:Lu AF60097 binding poses was
carried out on the last 300 ns of each trajectory using the thermal_mmgbsa.py
script from Schrodinger suite (release 2017-2), which calculates Prime MM/GBSA
(version 4.8) for every frame in a trajectory using OPLS3 force field with
VSGB2.1 solvation model44. The values reported in the results section are averages
for all trajectories of each of the three S1:IMI/S2:Lu AF60097 poses.
MD simulations. hSERT models were placed into explicit 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine lipid bilayer (POPC) using the orientation of the
5I73 structure from the Orientation of Proteins in Membranes database45. Simple
point charge (SPC) water model46 was used to solvate the system, charges were
neutralized, and 0.15 M NaCl was added. The total system size was ∼135,000
atoms. Desmond MD systems (D. E. Shaw Research, New York, NY) with OPLS3
force field47 were used for the MD simulations. The system was initially minimized
and equilibrated with restraints on the ligand heavy atoms and protein backbone
atoms, followed by production runs at 310 K with all atoms unrestrained. The
NPγT ensemble was used with constant temperature (310 K) maintained with
Langevin dynamics, 1 atm constant pressure achieved with the hybrid Nose-
Hoover Langevin piston method48 on an anisotropic flexible periodic cell, and a
constant surface tension (x-y plane). Overall, 74 trajectories of with a total simu-
lation time of 125.28 μs were collected (Supplementary Table 1).
Conformational analysis. Distances and dihedral angles were calculated with
MDTraj (version 1.7.249), in combination with in-house Python scripts. Data sets
for conformational analyses were assembled as follows. We first combined data
from individual trajectories into a common pool for each simulated condition.
Then, for the histograms in Figs. 2g, h and 3f, g, we extracted 500 bootstrapped
samples of 5000 random frames each for a given simulated condition and plotted
averages and standard deviations of frequency distributions for those 500 samples.
For the ligand pairwise RMSD calculations (Fig. 2i) we carried out ten bootstrap
samplings, and extracted 500 frames for each sampling for each condition. For each
of the 500-frame bootstraps, all the frames are aligned pairwise for the RMSD
calculations, yielding a 500 × 500 matrix. The averages and standard deviations of
the ten bootstrapped samples are reported. For Supplementary Fig. 5, 50,000
random frames were extracted from the S1:S-CIT/S2:Lu AF60097 and S1:IMI/S2:
Lu AF60097 conditions (for the latter, we selected and used the frames that have
the distance between the 2-oxo modification of the quinolinone moiety of AF60097
and the side chain oxygen of Ser404 greater than 4.5 Å).
Microdialysis experiments. Sprague Dawley rats weighing 300–400 g is anes-
thetized with Hypnorm/Midazolam (2 ml/kg) and intracerebral guide cannulas are
stereotaxically implanted into the brain, aiming to position the guide cannula tip in
the ventral hippocampus (co-ordinates: −5.6 mm posterior to bregma, lateral
−4.8 mm, −4.0 mm ventral to dura) according to Paxinos and Watson. Anchor
screws and dental cement are used for fixation of the guide cannulas. The body
temperature of the animals is maintained at 37 °C using a homoeothermic blanket.
Rats recovered from surgery for 2–3 days, single-housed.
On the day of the experiment a microdialysis probe (CMA/12, 0.5 mm
diameter, 3 mm membrane length, non-metal) is inserted through the guide
cannula. The probes are connected via a dual swivel to a microinjection pump.
Perfusion of the microdialysis probe with filtered Ringer solution (145 mm NaCl,
3 mM KCl 1 mMMgCl2, 1.2 mM CaCl2) begin shortly before insertion of the probe
into the brain and continued for the duration of the experiment at a constant flow
rate. After stabilization, the experiments are initiated. The experimental design
consisted of collection of brain dialysate samples in 20 min fractions. Prior to the
first sample collection the probes had been perfused for 180 min. A total of 12
fractions were sampled (four basal fractions and eight fractions after perfusion
start) and the dialysate 5-HT content was analyzed using HPLC detection.
Perfusion solutions contained Lu AF60097, imipramine, a combination of the two,
or vehicle (artificial cerebrospinal fluid (aCSF)). After the experiments, the animals
are euthanized.
The concentration of 5-HT in the dialysates was determined by means of HPLC
with electrochemical detection. The monoamines were separated by reverse phase
liquid chromatography (ODS 160 × 3.0 mm column) and analyzed using a mobile
phase consisting of 150 mM NaH2PO4, 4.8 mM citric acid monohydrate, 3 mM
dodecyl sulfate, 50 μM EDTA, 8 mM NaCl, 11.3% methanol and 16.7% acetonitrile
(pH 5.6); flow rate of 0.4 ml/min. Electrochemical detection was accomplished
using a coulometric detector and a SenCell (Antec); potential set at E1= 500 mV
(Coulochem III, ESA).
All experiments involving research animals were performed in accordance with
guidelines from the Danish Animal Experimentation Inspectorate and approved by
the local ethical committee.
Data calculation. The allosteric potency was calculated as previously described21.
The dissociation rate constants (k[drug]) at indicated unlabeled ligand concentra-
tions were calculated and expressed relative to the dissociation rate constant
without the presence of unlabeled ligand (kbuffer). The allosteric potency was
determined as the drug concentration that impairs the dissociation rate by 50%
compared with dissociation in buffer. IC50 values were calculated from con-
centration effect curves of normalized dissociation ratio (k[drug]/kbuffer) versus log
[drug] and are shown as mean values calculated from means of pIC50 and the SE
interval from the pIC50 ± S.E. All data were analyzed by linear or nonlinear
regression analysis using Prism 7.0 (GraphPad Software Inc., San Diego, CA).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data avaliability
Data supporting the findings of this manuscript are available from the corresponding
authors upon reasonable request. A reporting summary for this article is available as
a Supplementary Information file.
The source data underlying Figs. 1b–e, 3b–c, 4b, 5a, 6 and Supplementary Fig. 6 are
provided as a Source Data File.
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